Codexis, a developer of industrial enzymes to enable the production of bio-based chemicals and pharmaceutical intermediates, has appointed John Nicols as president and ceo.
Nicols was previously senior vice president, Strategic Development and Catalysts, at specialist chemical firm Albemarle.
In total he spent more than 20 years at Albemarle, managing multiple divisions of the company, driving sustained growth in its Flame Retardants and Fine Chemistry business units. He completed a three-year assignment in Tokyo, Japan from 1995 to 1998 and also co-led a corporate strategy review that focused on driving the corporation’s organic new business development opportunities.
As a result of this project, Nicols was appointed as head of company wide Strategic Development.
